The Women TAF-FTC Benchmark Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The study seeks to assess the safety and define blood and tissue benchmark concentrations of Tenofovir (TFV) and Tenofovir diphosphate (TFV-DP) in Cisgender women using directly observed tenofovir alafenamide (TAF)-emtricitabine (TAF-FTC) pre-exposure prophylaxis (PrEP). These data will help accurate interpretation of efficacy results obtained in HIV prevention trials and programs in cisgender women.
Epistemonikos ID: e4970378b6f4ee30272d06cd5ab3107cfd8fe394
First added on: May 09, 2024